{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T12:01:28Z","timestamp":1794744088762,"version":"4.9.1"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,19]],"date-time":"2022-07-19T00:00:00Z","timestamp":1658188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,19]],"date-time":"2022-07-19T00:00:00Z","timestamp":1658188800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009539","name":"U-M | Life Sciences Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009539","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Pathogenic \u03b1-synuclein (\u03b1-syn) is a prion-like protein that drives the pathogenesis of Lewy Body Dementia (LBD) and Parkinson\u2019s Disease (PD). To target pathogenic \u03b1-syn preformed fibrils (PFF), here we designed extracellular disulfide bond-free synthetic nanobody libraries in yeast. Following selection, we identified a nanobody, PFFNB2, that can specifically recognize \u03b1-syn PFF over \u03b1-syn monomers. PFFNB2 cannot inhibit the aggregation of \u03b1-syn monomer, but can significantly dissociate \u03b1-syn fibrils. Furthermore, adeno-associated virus (AAV)-encoding EGFP fused to PFFNB2 (AAV-EGFP-PFFNB2) can inhibit PFF-induced \u03b1-syn serine 129 phosphorylation (pS129) in mouse primary cortical neurons, and prevent \u03b1-syn pathology spreading to the cortex in the transgenic mice expressing human wild type (WT) \u03b1-syn by intrastriatal-PFF injection. The pS129 immunoreactivity is negatively correlated with the expression of AAV-EGFP-PFFNB2. In conclusion, PFFNB2 holds a promise for mechanistic exploration and therapeutic development in \u03b1-syn-related pathogenesis.<\/jats:p>","DOI":"10.1038\/s41467-022-31787-2","type":"journal-article","created":{"date-parts":[[2022,7,19]],"date-time":"2022-07-19T10:03:15Z","timestamp":1658224995000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":78,"title":["\u03b1-Synuclein fibril-specific nanobody reduces prion-like \u03b1-synuclein spreading in mice"],"prefix":"10.1038","volume":"13","author":[{"given":"Yemima R.","family":"Butler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7566-8529","authenticated-orcid":false,"given":"Yuqing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramhari","family":"Kumbhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiran","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kundlik","family":"Gadhave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanmei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6587-556X","authenticated-orcid":false,"given":"Xiaobo","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6025-9848","authenticated-orcid":false,"given":"Wenjing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,19]]},"reference":[{"key":"31787_CR1","first-page":"879","volume":"152","author":"M Baba","year":"1998","unstructured":"Baba, M. et al. Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson\u2019s disease and dementia with Lewy bodies. Am. J. Pathol. 152, 879\u2013884 (1998).","journal-title":"Am. J. Pathol."},{"key":"31787_CR2","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s00415-008-5007-0","volume":"255","author":"R Dodel","year":"2008","unstructured":"Dodel, R. et al. Lewy body dementia and Parkinson\u2019s disease with dementia. J. Neurol. 255, 39\u201347 (2008).","journal-title":"J. Neurol."},{"key":"31787_CR3","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/s41582-018-0107-7","volume":"15","author":"NA Arnaoutoglou","year":"2019","unstructured":"Arnaoutoglou, N. A., O\u2019Brien, J. T. & Underwood, B. R. Dementia with Lewy bodies \u2014 from scientific knowledge to clinical insights. Nat. Rev. Neurol. 15, 103\u2013112 (2019).","journal-title":"Nat. Rev. Neurol."},{"key":"31787_CR4","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1212\/WNL.51.2.351","volume":"51","author":"JM Olichney","year":"1998","unstructured":"Olichney, J. M. et al. Cognitive decline is faster in Lewy body variant than in Alzheimer\u2019s disease. Neurology 51, 351\u2013357 (1998).","journal-title":"Neurology"},{"key":"31787_CR5","doi-asserted-by":"publisher","first-page":"II3","DOI":"10.1007\/PL00007758","volume":"247","author":"H Braak","year":"2000","unstructured":"Braak, H. & Braak, E. Pathoanatomy of Parkinson\u2019s disease. J. Neurol. 247, II3\u2013II10 (2000).","journal-title":"J. Neurol."},{"key":"31787_CR6","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","volume":"24","author":"H Braak","year":"2003","unstructured":"Braak, H. et al. Staging of brain pathology related to sporadic Parkinson\u2019s disease. Neurobiol. Aging 24, 197\u2013211 (2003).","journal-title":"Neurobiol. Aging"},{"key":"31787_CR7","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/nm1746","volume":"14","author":"J-Y Li","year":"2008","unstructured":"Li, J.-Y. et al. Lewy bodies in grafted neurons in subjects with Parkinson\u2019s disease suggest host-to-graft disease propagation. Nat. Med. 14, 501\u2013503 (2008).","journal-title":"Nat. Med."},{"key":"31787_CR8","doi-asserted-by":"publisher","first-page":"6544","DOI":"10.1073\/pnas.1605245113","volume":"113","author":"W Li","year":"2016","unstructured":"Li, W. et al. Extensive graft-derived dopaminergic innervation is maintained 24 years after transplantation in the degenerating parkinsonian brain. Proc. Natl Acad. Sci. 113, 6544\u20136549 (2016).","journal-title":"Proc. Natl Acad. Sci."},{"key":"31787_CR9","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1038\/nm1747","volume":"14","author":"JH Kordower","year":"2008","unstructured":"Kordower, J. H., Chu, Y., Hauser, R. A., Freeman, T. B. & Olanow, C. W. Lewy body\u2013like pathology in long-term embryonic nigral transplants in Parkinson\u2019s disease. Nat. Med. 14, 504\u2013506 (2008).","journal-title":"Nat. Med."},{"key":"31787_CR10","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.neuron.2011.08.033","volume":"72","author":"LA Volpicelli-Daley","year":"2011","unstructured":"Volpicelli-Daley, L. A. et al. Exogenous \u03b1-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron 72, 57\u201371 (2011).","journal-title":"Neuron"},{"key":"31787_CR11","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1126\/science.1227157","volume":"338","author":"KC Luk","year":"2012","unstructured":"Luk, K. C. et al. Pathological \u03b1-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Sci. (80-.). 338, 949\u2013953 (2012).","journal-title":"Sci. (80-.)."},{"key":"31787_CR12","doi-asserted-by":"publisher","first-page":"aah3374","DOI":"10.1126\/science.aah3374","volume":"353","author":"X Mao","year":"2016","unstructured":"Mao, X. et al. Pathological \u03b1-synuclein transmission initiated by binding lymphocyte-activation gene 3. Sci. (80-.). 353, aah3374\u2013aah3374 (2016).","journal-title":"Sci. (80-.)."},{"key":"31787_CR13","doi-asserted-by":"publisher","first-page":"eaat8407","DOI":"10.1126\/science.aat8407","volume":"362","author":"T-I Kam","year":"2018","unstructured":"Kam, T.-I. et al. Poly(ADP-ribose) drives pathologic \u03b1-synuclein neurodegeneration in Parkinson\u2019s disease. Sci. (80-.). 362, eaat8407 (2018).","journal-title":"Sci. (80-.)."},{"key":"31787_CR14","doi-asserted-by":"publisher","first-page":"101027","DOI":"10.1016\/j.nantod.2020.101027","volume":"36","author":"Y-Q Liu","year":"2021","unstructured":"Liu, Y.-Q. et al. Nanozyme scavenging ROS for prevention of pathologic \u03b1-synuclein transmission in Parkinson\u2019s disease. Nano Today 36, 101027 (2021).","journal-title":"Nano Today"},{"key":"31787_CR15","doi-asserted-by":"publisher","first-page":"6096","DOI":"10.1021\/acsabm.0c00684","volume":"3","author":"L Jia","year":"2020","unstructured":"Jia, L. et al. Molecular Mediation of Prion-like \u03b1-Synuclein Fibrillation from Toxic PFFs to Nontoxic Species. ACS Appl. Bio. Mater. 3, 6096\u20136102 (2020).","journal-title":"ACS Appl. Bio. Mater."},{"key":"31787_CR16","doi-asserted-by":"publisher","first-page":"8338","DOI":"10.3390\/ijms22158338","volume":"22","author":"A Jan","year":"2021","unstructured":"Jan, A., Gon\u00e7alves, N. P., Vaegter, C. B., Jensen, P. H. & Ferreira, N. The prion-like spreading of alpha-synuclein in Parkinson\u2019s Disease: update on models and hypotheses. Int. J. Mol. Sci. 22, 8338 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"31787_CR17","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1074\/jbc.M107045200","volume":"277","author":"H-J Lee","year":"2002","unstructured":"Lee, H.-J., Choi, C. & Lee, S.-J. Membrane-bound \u03b1-synuclein has a high aggregation propensity and the ability to seed the aggregation of the cytosolic form. J. Biol. Chem. 277, 671\u2013678 (2002).","journal-title":"J. Biol. Chem."},{"key":"31787_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/nm.4269","volume":"23","author":"YC Wong","year":"2017","unstructured":"Wong, Y. C. & Krainc, D. \u03b1-synuclein toxicity in neurodegeneration: mechanism and therapeutic strategies. Nat. Med. 23, 1\u201313 (2017).","journal-title":"Nat. Med."},{"key":"31787_CR19","doi-asserted-by":"crossref","unstructured":"Gu, H. et al. Lymphocyte Activation Gene 3 (Lag3) Contributes to \u03b1-Synucleinopathy in \u03b1-Synuclein Transgenic Mice. Front. Cell. Neurosci. 15, 656426 (2021).","DOI":"10.3389\/fncel.2021.656426"},{"key":"31787_CR20","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1111\/jnc.14713","volume":"150","author":"NN Vaikath","year":"2019","unstructured":"Vaikath, N. N. et al. Antibodies against alpha\u2010synuclein: tools and therapies. J. Neurochem. 150, 612\u2013625 (2019).","journal-title":"J. Neurochem."},{"key":"31787_CR21","doi-asserted-by":"crossref","unstructured":"Slastnikova, T. A., Ulasov, A. V., Rosenkranz, A. A. & Sobolev, A. S. Targeted intracellular delivery of antibodies: the state of the art. Front. Pharmacol. 9, 1208 (2018).","DOI":"10.3389\/fphar.2018.01208"},{"key":"31787_CR22","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.3390\/microorganisms9091956","volume":"9","author":"N Silva-Pilipich","year":"2021","unstructured":"Silva-Pilipich, N., Smerdou, C. & Vanrell, L. A small virus to deliver small antibodies: new targeted therapies based on AAV delivery of nanobodies. Microorganisms 9, 1956 (2021).","journal-title":"Microorganisms"},{"key":"31787_CR23","doi-asserted-by":"publisher","first-page":"e19338","DOI":"10.1371\/journal.pone.0019338","volume":"6","author":"E Masliah","year":"2011","unstructured":"Masliah, E. et al. Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease. PLoS ONE 6, e19338 (2011).","journal-title":"PLoS ONE"},{"key":"31787_CR24","doi-asserted-by":"publisher","first-page":"13454","DOI":"10.1523\/JNEUROSCI.1292-12.2012","volume":"32","author":"E-J Bae","year":"2012","unstructured":"Bae, E.-J. et al. Antibody-aided clearance of extracellular \u03b1-synuclein prevents cell-to-cell aggregate transmission. J. Neurosci. 32, 13454\u201313469 (2012).","journal-title":"J. Neurosci."},{"key":"31787_CR25","doi-asserted-by":"publisher","first-page":"9441","DOI":"10.1523\/JNEUROSCI.5314-13.2014","volume":"34","author":"D Games","year":"2014","unstructured":"Games, D. et al. Reducing C-terminal-truncated alpha-synuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinson\u2019s Disease-like models. J. Neurosci. 34, 9441\u20139454 (2014).","journal-title":"J. Neurosci."},{"key":"31787_CR26","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1016\/j.celrep.2014.05.033","volume":"7","author":"HT Tran","year":"2014","unstructured":"Tran, H. T. et al. \u03b1-Synuclein immunotherapy blocks uptake and templated propagation of misfolded \u03b1-synuclein and neurodegeneration. Cell Rep. 7, 2054\u20132065 (2014).","journal-title":"Cell Rep."},{"key":"31787_CR27","doi-asserted-by":"publisher","first-page":"104712","DOI":"10.1016\/j.nbd.2019.104712","volume":"136","author":"MX Henderson","year":"2020","unstructured":"Henderson, M. X. et al. Characterization of novel conformation-selective \u03b1-synuclein antibodies as potential immunotherapeutic agents for Parkinson\u2019s disease. Neurobiol. Dis. 136, 104712 (2020).","journal-title":"Neurobiol. Dis."},{"key":"31787_CR28","doi-asserted-by":"publisher","first-page":"17","DOI":"10.4161\/mabs.4.1.18347","volume":"4","author":"H Liu","year":"2012","unstructured":"Liu, H. & May, K. Disulfide bond structures of IgG molecules. MAbs 4, 17\u201323 (2012).","journal-title":"MAbs"},{"key":"31787_CR29","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1001\/jamaneurol.2021.4161","volume":"79","author":"S Salloway","year":"2022","unstructured":"Salloway, S. et al. Amyloid-related imaging abnormalities in 2 Phase 3 studies evaluating Aducanumab in patients with early Alzheimer disease. JAMA Neurol. 79, 13 (2022).","journal-title":"JAMA Neurol."},{"key":"31787_CR30","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1110\/ps.34602","volume":"11","author":"M Dumoulin","year":"2009","unstructured":"Dumoulin, M. et al. Single-domain antibody fragments with high conformational stability. Protein Sci. 11, 500\u2013515 (2009).","journal-title":"Protein Sci."},{"key":"31787_CR31","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1146\/annurev-biochem-063011-092449","volume":"82","author":"S Muyldermans","year":"2013","unstructured":"Muyldermans, S. Nanobodies: natural single-domain antibodies. Annu. Rev. Biochem. 82, 775\u2013797 (2013).","journal-title":"Annu. Rev. Biochem."},{"key":"31787_CR32","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/363446a0","volume":"363","author":"C Hamers-Casterman","year":"1993","unstructured":"Hamers-Casterman, C. et al. Naturally occurring antibodies devoid of light chains. Nature 363, 446\u2013448 (1993).","journal-title":"Nature"},{"key":"31787_CR33","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3390\/antib8010005","volume":"8","author":"L Jank","year":"2019","unstructured":"Jank, L. et al. Current approaches and future perspectives for nanobodies in stroke diagnostic and therapy. Antibodies 8, 5 (2019).","journal-title":"Antibodies"},{"key":"31787_CR34","doi-asserted-by":"crossref","unstructured":"Dong, J.-X. et al. A toolbox of nanobodies developed and validated for use as intrabodies and nanoscale immunolabels in mammalian brain neurons. Elife 8, e48750 (2019).","DOI":"10.7554\/eLife.48750"},{"key":"31787_CR35","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s13311-013-0193-6","volume":"10","author":"A Messer","year":"2013","unstructured":"Messer, A. & Joshi, S. N. Intrabodies as neuroprotective therapeutics. Neurotherapeutics 10, 447\u2013458 (2013).","journal-title":"Neurotherapeutics"},{"key":"31787_CR36","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s40259-020-00419-w","volume":"34","author":"C Zhang","year":"2020","unstructured":"Zhang, C., \u00d6tjengerdes, R. M., Roewe, J., Mejias, R. & Marschall, A. L. J. Applying antibodies inside cells: principles and recent advances in neurobiology, virology and oncology. BioDrugs 34, 435\u2013462 (2020).","journal-title":"BioDrugs"},{"key":"31787_CR37","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s12104-009-9182-4","volume":"3","author":"A Vuchelen","year":"2009","unstructured":"Vuchelen, A. et al. 1H, 13C and 15N assignments of a camelid nanobody directed against human \u03b1-synuclein. Biomol. NMR Assign. 3, 231\u2013233 (2009).","journal-title":"Biomol. NMR Assign."},{"key":"31787_CR38","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.1016\/j.jmb.2013.01.040","volume":"425","author":"T Guilliams","year":"2013","unstructured":"Guilliams, T. et al. Nanobodies raised against monomeric \u03b1-synuclein distinguish between fbrils at different maturation stages. J. Mol. Biol. 425, 2397\u20132411 (2013).","journal-title":"J. Mol. Biol."},{"key":"31787_CR39","doi-asserted-by":"crossref","unstructured":"Butler, D. C. et al. Bifunctional anti-non-amyloid component \u03b1-synuclein nanobodies are protective in situ. PLoS ONE 11, e0165964 (2016).","DOI":"10.1371\/journal.pone.0165964"},{"key":"31787_CR40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41531-017-0038-9","volume":"4","author":"D Chatterjee","year":"2018","unstructured":"Chatterjee, D. et al. Proteasome-targeted nanobodies alleviate pathology and functional decline in an \u03b1-synuclein-based Parkinson\u2019s disease model. npj Park. Dis. 4, 1\u201310 (2018).","journal-title":"npj Park. Dis."},{"key":"31787_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7554\/eLife.16228","volume":"5","author":"S Moutel","year":"2016","unstructured":"Moutel, S. et al. NaLi-H1: a universal synthetic library of humanized nanobodies providing highly functional antibodies and intrabodies. Elife 5, 1\u201331 (2016).","journal-title":"Elife"},{"key":"31787_CR42","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/s41594-018-0028-6","volume":"25","author":"C McMahon","year":"2018","unstructured":"McMahon, C. et al. Yeast surface display platform for rapid discovery of conformationally selective nanobodies. Nat. Struct. Mol. Biol. 25, 289\u2013296 (2018).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"31787_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-26338-z","volume":"8","author":"P Kunz","year":"2018","unstructured":"Kunz, P. et al. The structural basis of nanobody unfolding reversibility and thermoresistance. Sci. Rep. 8, 7934 (2018).","journal-title":"Sci. Rep."},{"key":"31787_CR44","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1038\/nprot.2014.143","volume":"9","author":"LA Volpicelli-Daley","year":"2014","unstructured":"Volpicelli-Daley, L. A., Luk, K. C. & Lee, V. M. Y. Addition of exogenous \u03b1-synuclein preformed fibrils to primary neuronal cultures to seed recruitment of endogenous \u03b1-synuclein to Lewy body and Lewy neurite-like aggregates. Nat. Protoc. 9, 2135\u20132146 (2014).","journal-title":"Nat. Protoc."},{"key":"31787_CR45","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.jsb.2005.06.006","volume":"151","author":"R Khurana","year":"2005","unstructured":"Khurana, R. et al. Mechanism of thioflavin T binding to amyloid fibrils. J. Struct. Biol. 151, 229\u2013238 (2005).","journal-title":"J. Struct. Biol."},{"key":"31787_CR46","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1021\/cn200006h","volume":"2","author":"X Mao","year":"2011","unstructured":"Mao, X. et al. Binding Modes of Thioflavin T Molecules to Prion Peptide Assemblies Identified by Using Scanning Tunneling Microscopy. ACS Chem. Neurosci. 2, 281\u2013287 (2011).","journal-title":"ACS Chem. Neurosci."},{"key":"31787_CR47","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/nsmb.1727","volume":"17","author":"A Kirchhofer","year":"2010","unstructured":"Kirchhofer, A. et al. Modulation of protein properties in living cells using nanobodies. Nat. Struct. Mol. Biol. 17, 133\u2013138 (2010).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"31787_CR48","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.jmb.2008.01.022","volume":"377","author":"D Saerens","year":"2008","unstructured":"Saerens, D., Conrath, K., Govaert, J. & Muyldermans, S. Disulfide bond introduction for general stabilization of immunoglobulin heavy-chain variable domains. J. Mol. Biol. 377, 478\u2013488 (2008).","journal-title":"J. Mol. Biol."},{"key":"31787_CR49","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1038\/nbt.3909","volume":"35","author":"W Wang","year":"2017","unstructured":"Wang, W. et al. A light- and calcium-gated transcription factor for imaging and manipulating activated neurons. Nat. Biotechnol. 35, 864\u2013871 (2017).","journal-title":"Nat. Biotechnol."},{"key":"31787_CR50","doi-asserted-by":"publisher","first-page":"2970","DOI":"10.1172\/JCI85456","volume":"126","author":"S Brahmachari","year":"2016","unstructured":"Brahmachari, S. et al. Activation of tyrosine kinase c-Abl contributes to \u03b1-synuclein-induced neurodegeneration. J. Clin. Investig. 126, 2970\u20132988 (2016).","journal-title":"J. Clin. Investig."},{"key":"31787_CR51","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1126\/science.276.5321.2045","volume":"276","author":"MH Polymeropoulos","year":"1997","unstructured":"Polymeropoulos, M. H. et al. Mutation in the \u03b1-synuclein gene identified in families with Parkinson\u2019s disease. Sci. (80-.). 276, 2045\u20132047 (1997).","journal-title":"Sci. (80-.)."},{"key":"31787_CR52","doi-asserted-by":"publisher","first-page":"20051","DOI":"10.1073\/pnas.0908005106","volume":"106","author":"KC Luk","year":"2009","unstructured":"Luk, K. C. et al. Exogenous \u03b1-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells. Proc. Natl Acad. Sci. USA 106, 20051\u201320056 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"31787_CR53","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/ncb748","volume":"4","author":"H Fujiwara","year":"2002","unstructured":"Fujiwara, H. et al. \u03b1-Synuclein is phosphorylated in synucleinopathy lesions. Nat. Cell Biol. 4, 160\u2013164 (2002).","journal-title":"Nat. Cell Biol."},{"key":"31787_CR54","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1369\/0022155416673995","volume":"65","author":"CR Scalia","year":"2017","unstructured":"Scalia, C. R. et al. Antigen masking during fixation and embedding, dissected. J. Histochem. Cytochem. 65, 5\u201320 (2017).","journal-title":"J. Histochem. Cytochem."},{"key":"31787_CR55","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/S1044-7431(03)00198-2","volume":"24","author":"S Gispert","year":"2003","unstructured":"Gispert, S. et al. Transgenic mice expressing mutant A53T human alpha-synuclein show neuronal dysfunction in the absence of aggregate formation. Mol. Cell. Neurosci. 24, 419\u2013429 (2003).","journal-title":"Mol. Cell. Neurosci."},{"key":"31787_CR56","doi-asserted-by":"publisher","first-page":"3235","DOI":"10.1093\/brain\/awu291","volume":"137","author":"I Fishbein","year":"2014","unstructured":"Fishbein, I., Kuo, Y.-M., Giasson, B. I. & Nussbaum, R. L. Augmentation of phenotype in a transgenic Parkinson mouse heterozygous for a Gaucher mutation. Brain 137, 3235\u20133247 (2014).","journal-title":"Brain"},{"key":"31787_CR57","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1177\/16.11.673","volume":"16","author":"ED Eanes","year":"1968","unstructured":"Eanes, E. D. & Glenner, G. G. X-ray diffraction studies on amyloid filaments. J. Histochem. Cytochem. 16, 673\u2013677 (1968).","journal-title":"J. Histochem. Cytochem."},{"key":"31787_CR58","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-38271-2","volume":"9","author":"T Skamris","year":"2019","unstructured":"Skamris, T., Marasini, C., Madsen, K. L., Foder\u00e0, V. & Vestergaard, B. Early stage alpha-synuclein amyloid fibrils are reservoirs of membrane-binding species. Sci. Rep. 9, 1733 (2019).","journal-title":"Sci. Rep."},{"key":"31787_CR59","doi-asserted-by":"publisher","unstructured":"Kim, J.-Y., Grunke, S.D., Levites, Y., Golde, T.E. & Jankowsky, J.L. Intracerebroventricular viral injection of the neonatal mouse brain for persistent and widespread neuronal transduction. J. Vis. Exp. https:\/\/doi.org\/10.3791\/51863 (2014).","DOI":"10.3791\/51863"},{"key":"31787_CR60","doi-asserted-by":"publisher","first-page":"8797","DOI":"10.1523\/JNEUROSCI.22-20-08797.2002","volume":"22","author":"DE Cabin","year":"2002","unstructured":"Cabin, D. E. et al. Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking \u03b1-synuclein. J. Neurosci. 22, 8797\u20138807 (2002).","journal-title":"J. Neurosci."},{"key":"31787_CR61","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S0896-6273(00)80886-7","volume":"25","author":"A Abeliovich","year":"2000","unstructured":"Abeliovich, A. et al. Mice lacking \u03b1-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 25, 239\u2013252 (2000).","journal-title":"Neuron"},{"key":"31787_CR62","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/nrn3406","volume":"14","author":"HA Lashuel","year":"2013","unstructured":"Lashuel, H. A., Overk, C. R., Oueslati, A. & Masliah, E. The many faces of \u03b1-synuclein: from structure and toxicity to therapeutic target. Nat. Rev. Neurosci. 14, 38\u201348 (2013).","journal-title":"Nat. Rev. Neurosci."},{"key":"31787_CR63","doi-asserted-by":"publisher","first-page":"3214","DOI":"10.1523\/JNEUROSCI.20-09-03214.2000","volume":"20","author":"DD Murphy","year":"2000","unstructured":"Murphy, D. D., Rueter, S. M., Trojanowski, J. Q. & Lee, V. M.-Y. Synucleins are developmentally expressed, and \u03b1-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons. J. Neurosci. 20, 3214\u20133220 (2000).","journal-title":"J. Neurosci."},{"key":"31787_CR64","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/nature10324","volume":"477","author":"T Bartels","year":"2011","unstructured":"Bartels, T., Choi, J. G. & Selkoe, D. J. \u03b1-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature 477, 107\u2013110 (2011).","journal-title":"Nature"},{"key":"31787_CR65","doi-asserted-by":"publisher","first-page":"17797","DOI":"10.1073\/pnas.1113260108","volume":"108","author":"W Wang","year":"2011","unstructured":"Wang, W. et al. A soluble -synuclein construct forms a dynamic tetramer. Proc. Natl Acad. Sci. 108, 17797\u201317802 (2011).","journal-title":"Proc. Natl Acad. Sci."},{"key":"31787_CR66","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1038\/nature14547","volume":"522","author":"W Peelaerts","year":"2015","unstructured":"Peelaerts, W. et al. \u03b1-synuclein strains cause distinct synucleinopathies after local and systemic administration. Nature 522, 340\u2013344 (2015).","journal-title":"Nature"},{"key":"31787_CR67","doi-asserted-by":"publisher","first-page":"134316","DOI":"10.1016\/j.neulet.2019.134316","volume":"709","author":"MX Henderson","year":"2019","unstructured":"Henderson, M. X., Trojanowski, J. Q. & Lee, V. M.-Y. \u03b1-Synuclein pathology in Parkinson\u2019s disease and related \u03b1-synucleinopathies. Neurosci. Lett. 709, 134316 (2019).","journal-title":"Neurosci. Lett."},{"key":"31787_CR68","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1016\/j.jmb.2007.02.089","volume":"368","author":"S Emadi","year":"2007","unstructured":"Emadi, S., Barkhordarian, H., Wang, M. S., Schulz, P. & Sierks, M. R. Isolation of a human single chain antibody fragment against oligomeric \u03b1-synuclein that inhibits aggregation and prevents \u03b1-synuclein-induced toxicity. J. Mol. Biol. 368, 1132\u20131144 (2007).","journal-title":"J. Mol. Biol."},{"key":"31787_CR69","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.neulet.2009.04.046","volume":"459","author":"B Yuan","year":"2009","unstructured":"Yuan, B. & Sierks, M. R. Intracellular targeting and clearance of oligomeric alpha-synuclein alleviates toxicity in mammalian cells. Neurosci. Lett. 459, 16\u201318 (2009).","journal-title":"Neurosci. Lett."},{"key":"31787_CR70","doi-asserted-by":"crossref","unstructured":"Zhang, S. et al. Mechanistic basis for receptor-mediated pathological \u03b1-synuclein fibril cell-to-cell transmission in Parkinson\u2019s disease. Proc. Natl. Acad. Sci. 118, e2011196118 (2021).","DOI":"10.1073\/pnas.2011196118"},{"key":"31787_CR71","doi-asserted-by":"publisher","unstructured":"Mao, X. et al. Aplp1 and the Aplp1-Lag3 complex facilitates transmission of pathologic \u03b1-synuclein. bioRxiv 2021.05.01.442157 https:\/\/doi.org\/10.1101\/2021.05.01.442157 (2021).","DOI":"10.1101\/2021.05.01.442157"},{"key":"31787_CR72","doi-asserted-by":"crossref","unstructured":"Schenk, D. B. et al. First-in-human assessment of PRX002, an anti-a-synuclein monoclonal antibody, in healthy volunteers. Mov. Disord. 32, 211\u2013218 (2017).","DOI":"10.1002\/mds.26878"},{"key":"31787_CR73","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1001\/jamaneurol.2018.1487","volume":"75","author":"J Jankovic","year":"2018","unstructured":"Jankovic, J. et al. Safety and tolerability of multiple ascending doses of PRX002\/RG7935, an anti\u2013\u03b1-synuclein monoclonal antibody, in patients with Parkinson disease. JAMA Neurol. 75, 1206 (2018).","journal-title":"JAMA Neurol."},{"key":"31787_CR74","doi-asserted-by":"publisher","first-page":"104582","DOI":"10.1016\/j.nbd.2019.104582","volume":"132","author":"DJ Schofield","year":"2019","unstructured":"Schofield, D. J. et al. Preclinical development of a high affinity \u03b1-synuclein antibody, MEDI1341, that can enter the brain, sequester extracellular \u03b1-synuclein and attenuate \u03b1-synuclein spreading in vivo. Neurobiol. Dis. 132, 104582 (2019).","journal-title":"Neurobiol. Dis."},{"key":"31787_CR75","doi-asserted-by":"crossref","unstructured":"Frenzel, A., Hust, M. & Schirrmann, T. Expression of recombinant antibodies. Front. Immunol. 4, 217 (2013).","DOI":"10.3389\/fimmu.2013.00217"},{"key":"31787_CR76","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/s41573-021-00139-y","volume":"20","author":"GC Terstappen","year":"2021","unstructured":"Terstappen, G. C., Meyer, A. H., Bell, R. D. & Zhang, W. Strategies for delivering therapeutics across the blood\u2013brain barrier. Nat. Rev. Drug Discov. 20, 362\u2013383 (2021).","journal-title":"Nat. Rev. Drug Discov."},{"key":"31787_CR77","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.abb.2012.04.023","volume":"526","author":"M Pellis","year":"2012","unstructured":"Pellis, M. et al. A bacterial-two-hybrid selection system for one-step isolation of intracellularly functional Nanobodies. Arch. Biochem. Biophys. 526, 114\u2013123 (2012).","journal-title":"Arch. Biochem. Biophys."},{"key":"31787_CR78","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1038\/nprot.2006.94","volume":"1","author":"G Chao","year":"2006","unstructured":"Chao, G. et al. Isolating and engineering human antibodies using yeast surface display. Nat. Protoc. 1, 755\u2013768 (2006).","journal-title":"Nat. Protoc."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-31787-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-31787-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-31787-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T18:04:44Z","timestamp":1669313084000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-31787-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,19]]},"references-count":78,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["31787"],"URL":"https:\/\/doi.org\/10.1038\/s41467-022-31787-2","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,19]]},"assertion":[{"value":"31 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare the following competing interests: patent application filed by W.W., X.M., Y.B., Y.L., and R.K. with title \u2018Compositions and methods for treating alpha-synucleinopathies.\u2019 U.S. Provisional Patent Application No. 63\/222,141, filed Jul 15, 2021. Applicants: The Regents of the University of Michigan and The Johns Hopkins University. Patent pending. Some aspects of this paper is included in the patent such as disulfide-bond free PFFNB, AAV delivery of PFFNB2 to treat Parkinson\u2019s Disease. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4060"}}